| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 7.40 | 12.42 | 14.41 | 9.19 | 20.07 | 46.57 | 7.54 | 5.63 | — | 10.48 | 10.90 | 25.34 |
| Quick Ratio | 7.40 | 12.42 | 14.41 | 9.19 | 20.07 | 46.57 | 7.54 | 5.63 | — | 10.48 | 10.90 | 25.34 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -56.26% | -30.63% | -48.34% | -104.49% | -21.04% | -11.97% | -169.16% | -97.05% | -67.43% | -141.33% | -73.05% | -22.51% |
| ROA | -26.99% | -20.40% | -45.28% | -94.80% | -20.23% | -11.57% | -146.47% | -82.61% | -62.78% | -127.55% | -66.33% | -21.62% |
| Asset Turnover | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Book Value / Share | 0.99 | 2.43 | 3.39 | 5.89 | 11.07 | — | — | — | — | 1.19 | 2.75 | 16.00 |
Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for transplantation, autoimmune diseases, and neurodegenerative conditions. The company's lead investigational product is tegoprubart, a humanized anti-CD40L antibody that targets the CD40 ligand pathway, a well-validated biological mechanism for immune regulation. Tegoprubart is being evaluated across multiple therapeutic areas, including kidney allograft transplantation through the Phase 2 BESTOW trial, islet cell transplantation for type 1 diabetes management, and xenotransplantation procedures. The company is also exploring applications in amyotrophic lateral sclerosis treatment. Eledon's clinical development strategy encompasses Phase 2 studies demonstrating promising kidney function outcomes and favorable safety profiles compared to standard immunosuppressive regimens. The company is advancing toward Phase 3 clinical trials and regulatory discussions with the FDA. Eledon maintains active collaborations with leading transplant centers and research institutions to expand its therapeutic potential across multiple indication areas.